China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a biosimilar version of Johnson & Johnson’s Simponi (golimumab), has been accepted for review by China’s National Medical Products Administration (NMPA). This marks a significant step forward in the development and commercialization of this anti-TNF alpha antibody in China.
BAT2506 Overview
BAT2506 is a biosimilar developed by Bio-Thera Solutions targeting Johnson & Johnson’s Simponi (golimumab). As an anti-TNF alpha antibody, it has the potential to provide an effective treatment option for patients with conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The acceptance of the market filing by the NMPA represents a crucial milestone in bringing this biosimilar to the Chinese market.
Global Partnerships
Bio-Thera Solutions has licensed BAT2506 to multiple overseas companies for development in regions including Latin America, Europe, and the US. One of the key partners is STADA Arzneimittel AG, highlighting the international recognition and potential of this biosimilar candidate.-Fineline Info & Tech
Leave a Reply